You are viewing the site in preview mode
Skip to main content
|
Variables
|
Whole study population
|
Propensity score-matched pairs
|
|---|
|
PLT < 100 (×109/L), n = 247
|
PLT ≥ 100 (×109/L), n = 335
|
P
|
PLT < 100 (×109/L), n = 201
|
PLT ≥ 100 (×109/L), n = 201
|
P
|
|---|
|
Age (years)
|
51.18 ± 11.04
|
49.36 ± 11.37
|
0.054
|
50.25 ± 11.38
|
50.06 ± 12.07
|
0.872
|
|
Male/female
|
207/40
|
288/47
|
0.482
|
173/28
|
164/37
|
0.278
|
|
AFP > 400 ng/mL
|
76 (30.8%)
|
100 (29.9%)
|
0.855
|
62 (30.8%)
|
63 (31.3%)
|
1.000
|
|
TBIL (μmol/L)
|
16.65 ± 6.70
|
14.33 ± 6.00
|
< 0.001
|
15.61 ± 5.51
|
15.57 ± 6.71
|
0.941
|
|
ALB (g/L)
|
41.53 ± 4.40
|
42.52 ± 5.03
|
0.014
|
42.15 ± 3.99
|
42.11 ± 4.41
|
0.921
|
|
ALT (IU/L)
|
47.82 ± 35.86
|
47.20 ± 46.75
|
0.862
|
48.44 ± 37.47
|
45.96 ± 42.20
|
0.533
|
|
AST (IU/L)
|
42.45 ± 25.12
|
39.48 ± 39.64
|
0.302
|
41.19 ± 25.29
|
39.38 ± 35.53
|
0.556
|
|
PT (s)
|
12.43 ± 1.20
|
12.02 ± 1.09
|
< 0.001
|
12.25 ± 1.14
|
12.17 ± 1.13
|
0.517
|
|
CREA (μmol/L)
|
77.23 ± 24.14
|
75.94 ± 14.13
|
0.422
|
77.11 ± 15.15
|
75.60 ± 15.28
|
0.318
|
|
Tumor size < 3 cm
|
140 (56.9%)
|
160 (47.8%)
|
0.036
|
106 (52.7%)
|
112 (55.7%)
|
0.617
|
|
Solitary tumor
|
212 (85.8%)
|
308 (91.9%)
|
0.021
|
180 (89.6%)
|
184 (91.5%)
|
0.610
|
|
Transfusion (+/−)
|
26/221
|
10/325
|
< 0.001
|
10/191
|
10/191
|
1.000
|
|
Cirrhosis (+/−)
|
231/16
|
270/65
|
< 0.001
|
186/15
|
187/14
|
1.000
|
|
MVI (+/−)
|
49/198
|
47/288
|
0.071
|
40/161
|
37/164
|
0.800
|
|
Poor differentiation
|
99 (40.1%)
|
113 (33.7%)
|
0.117
|
84 (41.8%)
|
79 (39.3%)
|
0.685
|
- PLT platelet counts, AFP alpha-fetoprotein, TBIL total bilirubin, ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, PT prothrombin time, CREA creatinine, MVI microvascular invasion
